José Benito de Vega | Grifols has had a very positive stock market performance in 2019, with a 35% revaluation compared to 9% of the IBEX35. The positive evolution of its results, its powerful cash flow generation and debt reduction, together with its potential growth thanks to a treatment for Alzheimer’s that is under study, explain the good behavior of the stock.
BofAML | We reiterate Buy on Grifols A&B for durable double-digit EPS growth driven by strong global plasma market position. Margin expansion is returning as plasma cost stabilises. AMBAR study in Alzheimer’s disease; may increase IG/Albumin demand through off-label use.
As a result of conversations maintained with Shanghai RAAS, Grifols has reached an agreement to buy assets through a share issue. The Spanish company will buy 26.2% of economic and voting rights in the Chinese firm (valued at €3.8 Bn). So, Shanghai RAAS’ capital will become: 26.7% Create Group, 26.2% Grifols and 25.8% RAAS China Limited.
The Spanish blood products company could invest 5 bn$ in the Chinese pharmaceutical company Shanghai RAAS Blood Products, leader in China, which specialises in the investigation, production and sales of plasma products. The operation would be formalised in Q219. Grifols would reinforce its position in China and would reduce its dependence on the US.
On Friday Grifols presented the results of its AMBAR (Alzheimer Management by Albumin Replacement) (phase IIb/III) study in Barcelona. AMBAR is an innovative possible treatment based on the therapeutic properties of plasma which has shown, statistically significantly, its effectiveness in slowing the progression Alzheimer in moderately affected patients.
Last week Grifols received a negative recommendation from the global broker UBS, referring to the potential negative impact the commercialisation of a new alternative treatment for autoimmune diseases could have on its sales of intravenous immunoglobin.
Spanish pharmaceutical and healthcare firm Grifols has obtained approval from the US Food and Drug Administration (FDA) to market the physiological saline solution which the company manufactures at its plant in Las Torres de Cotillas (Murcia). This is very positive for the group’s hospital division and, in particular, for its presence in the US.
There has been a lot of song and dance about extending the ‘Junker Plan’ to promote investments of up to 630 billion euros over the next six years. But the fact is that, up to now, projects worth 116 billion euros have been approved under the auspices of the Plan, according to the European Commission (EC)’s own estimates.
BARCELONA | 16.8% of sales generated in Latin America, Asia-Pacific and R.O.W., the USA and Canada account for 60.0% of sales and Europe represents 21.8%. 8% of sales generated in Spain.